Effects of sedative drug use on the dopamine system: a systematic review and meta-analysis of in vivo neuroimaging studies.
Alcoholism
/ diagnostic imaging
Corpus Striatum
/ diagnostic imaging
Dopamine Plasma Membrane Transport Proteins
/ metabolism
Humans
Marijuana Abuse
/ diagnostic imaging
Neuroimaging
Opioid-Related Disorders
/ diagnostic imaging
Receptors, Dopamine D2
/ metabolism
Receptors, Dopamine D3
/ metabolism
Journal
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology
ISSN: 1740-634X
Titre abrégé: Neuropsychopharmacology
Pays: England
ID NLM: 8904907
Informations de publication
Date de publication:
03 2019
03 2019
Historique:
received:
20
03
2018
accepted:
03
08
2018
revised:
31
07
2018
pubmed:
7
9
2018
medline:
18
12
2019
entrez:
7
9
2018
Statut:
ppublish
Résumé
Use of alcohol, cannabis and opioids is highly prevalent and is associated with global disease burden and high economic costs. The exact pathophysiology of abuse or addiction associated with these sedative substances is not completely understood, but previous research implicates the important role of the striatal dopamine system in the addiction process. Multiple studies investigated changes in the striatal dopamine systems of users of sedative substances, but currently these results are very heterogeneous. Therefore, we conducted a meta-analysis of in vivo neuroimaging studies investigating dopaminergic alterations in the striatum of users of alcohol, opioids or cannabis. Analyses for each substance were conducted separately for the availability of D2/D3 dopamine receptors, dopamine transporters and dopamine synthesis capacity. In total, 723 substance users and 752 healthy controls were included. The results indicated a significant lower striatal D2/D3 receptor availability in alcohol users compared to controls (g = 0.46) but no difference in dopamine transporter availability or dopamine synthesis capacity. Our analysis indicated that changes of dopamine receptors and transporters are moderated by the duration of abstinence. Comparing opioid users with controls revealed a significant lower D2/D3 receptor availability (g = 1.17) and a significantly lower transporter availability (g = 1.55) in opioid users. For cannabis users, there was no significant difference in receptor availability compared to controls and too few studies provided information on dopamine transporter availability or synthesis capacity. Our analysis provides strong evidence for a central role of the striatal dopamine system in use of alcohol or opioids. Further studies are needed to clarify the impact of the dopamine system in cannabis users.
Identifiants
pubmed: 30188512
doi: 10.1038/s41386-018-0191-9
pii: 10.1038/s41386-018-0191-9
pmc: PMC6372711
doi:
Substances chimiques
Dopamine Plasma Membrane Transport Proteins
0
Receptors, Dopamine D2
0
Receptors, Dopamine D3
0
Types de publication
Journal Article
Meta-Analysis
Research Support, Non-U.S. Gov't
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
660-667Références
Mol Psychiatry. 1999 Mar;4(2):189-91, 104-5
pubmed: 10208452
Am J Psychiatry. 2000 Jan;157(1):127-9
pubmed: 10618027
Psychopharmacology (Berl). 1999 Dec;147(3):314-8
pubmed: 10639691
J Addict Dis. 2001;20(4):91-6
pubmed: 11760929
Psychiatry Res. 2002 Dec 30;116(3):163-72
pubmed: 12477600
Synapse. 2003 Sep 15;49(4):226-31
pubmed: 12827641
Am J Psychiatry. 2004 Oct;161(10):1783-9
pubmed: 15465974
Life Sci. 2005 May 27;77(2):130-9
pubmed: 15862598
Biol Psychiatry. 2005 Nov 15;58(10):779-86
pubmed: 16018986
Am J Psychiatry. 2005 Aug;162(8):1515-20
pubmed: 16055774
Addict Biol. 2005 Sep;10(3):293-7
pubmed: 16109593
Arch Gen Psychiatry. 2006 Sep;63(9):999-1008
pubmed: 16953002
Curr Opin Pharmacol. 2007 Feb;7(1):69-76
pubmed: 17174602
Eur J Pharmacol. 2008 Jan 28;579(1-3):160-6
pubmed: 17977528
J Neurosci. 2007 Nov 14;27(46):12700-6
pubmed: 18003850
Eur Neuropsychopharmacol. 2008 Apr;18(4):262-70
pubmed: 18077142
Psychopharmacology (Berl). 2008 May;197(4):549-56
pubmed: 18270689
J Neurosci. 2008 Aug 20;28(34):8454-61
pubmed: 18716203
Neuropsychopharmacology. 2009 Sep;34(10):2218-26
pubmed: 19440191
Biol Psychiatry. 2010 Feb 1;67(3):275-8
pubmed: 19811777
Psychiatry Res. 2010 Dec 30;184(3):192-5
pubmed: 21050726
Drug Alcohol Depend. 2011 Nov 1;118(2-3):148-51
pubmed: 21477952
Biol Psychiatry. 2011 Oct 15;70(8):770-6
pubmed: 21802658
Addict Biol. 2012 Nov;17(6):981-90
pubmed: 21812871
Psychopharmacology (Berl). 2012 Mar;220(1):55-64
pubmed: 21881874
Biol Psychiatry. 2012 Feb 1;71(3):192-8
pubmed: 22015315
Addict Biol. 2012 Mar;17(2):490-503
pubmed: 22023291
Biol Psychiatry. 2012 Apr 15;71(8):677-83
pubmed: 22290115
Arch Gen Psychiatry. 2012 Aug;69(8):776-86
pubmed: 22474070
Drug Alcohol Depend. 2013 Feb 1;128(1-2):52-7
pubmed: 22909787
Pharmacopsychiatry. 2013 Jun;46(4):130-6
pubmed: 23364872
Psychopharmacology (Berl). 2013 Nov;230(2):235-44
pubmed: 23715641
Biol Psychiatry. 2014 Mar 15;75(6):470-8
pubmed: 23820822
Neuropharmacology. 2014 Jan;76 Pt B:498-509
pubmed: 23851257
Neuropsychopharmacology. 2014 Jun;39(7):1703-12
pubmed: 24469594
Addiction. 2014 Aug;109(8):1320-33
pubmed: 24661272
Proc Natl Acad Sci U S A. 2014 Jul 29;111(30):E3149-56
pubmed: 25024177
Br J Psychiatry. 2014 Jun;204(6):420-9
pubmed: 25029687
Psychopharmacology (Berl). 2015 Jul;232(14):2597-607
pubmed: 25757673
Nat Rev Neurosci. 2015 May;16(5):305-12
pubmed: 25873042
Addict Biol. 2017 Jan;22(1):229-234
pubmed: 26040446
Hum Brain Mapp. 2015 Aug;36(8):3154-66
pubmed: 26058801
Psychopharmacology (Berl). 2015 Sep;232(18):3391-401
pubmed: 26096461
Neuroscience. 2015 Aug 20;301:529-41
pubmed: 26116518
Lancet Psychiatry. 2016 Aug;3(8):760-73
pubmed: 27475769
Neuropharmacology. 2017 Aug 1;122:175-188
pubmed: 28108358
Mol Psychiatry. 2017 May;22(5):666-679
pubmed: 28289283
JAMA Psychiatry. 2017 May 1;74(5):511-519
pubmed: 28297025
Neurobiol Aging. 2017 Sep;57:36-46
pubmed: 28599217
Neuropsychopharmacology. 2017 Nov;42(12):2325-2332
pubmed: 28643800
Proc Natl Acad Sci U S A. 1988 Jul;85(14):5274-8
pubmed: 2899326
Mol Psychiatry. 2018 Aug;23(8):1711-1716
pubmed: 29112197
Nat Med. 1995 Jul;1(7):654-7
pubmed: 7585146
Alcohol Clin Exp Res. 1996 Dec;20(9):1594-8
pubmed: 8986209
Neuropsychopharmacology. 1997 Feb;16(2):174-82
pubmed: 9015800
BMJ. 1997 Sep 13;315(7109):629-34
pubmed: 9310563
Eur J Nucl Med. 1997 Oct;24(10):1253-60
pubmed: 9323266
Mol Psychiatry. 1998 Mar;3(2):156-61
pubmed: 9577840
Neurosci Lett. 1998 Sep 11;253(3):195-7
pubmed: 9792244